Immune checkpoint blockade, which blocks the regulatory pathways that express on immune cells to improve antitumor immunological responses, is becoming one of the most promising approaches for antitumor therapy. This therapy has achieved important clinical advancement and provided a new opportunity against a variety of cancers. However, limitations of checkpoint inhibitors application, including the risk of autoimmune disease, low objective response rates, and high cost, still largely affect their broad applications in patients. Therefore, it is desirable to seek effective delivery methods to further enhance the therapeutic efficacy and reduce drawbacks of immune checkpoint blockade. This brief review summarizes strategies to increase the antitumor immunity, including the local and targeted delivery of checkpoint inhibitors, and a combination of different checkpoint inhibitors or with other therapeutic treatments.
Introduction
The immune system plays a critical role in protecting the body against various types of diseases including cancer. [1] A crucial member during immunotherapy is T cell, which can eliminate cancer cells by recognizing the tumor-associated antigens on their surface (CD8+ effector T cells, also called cytotoxic T lymphocytes (CTLs)) and orchestrating diverse immune responses (CD4+ helper T cells). [2] Effective activation of T cells involves multiple subsequent steps, including the recognition of peptidemajor histocompatibility complex (MHC) by T cell receptors (TCR), activation and proliferation in lymphoid tissues, trafficking to the site of tumor, and killing tumor cells. [3] Nevertheless, multiple mechanisms of immune suppression, such as insufficient dendritic cell (DC) activation and tumor-associated antigens presentation and overexpressed inhibitory ligands www.advancedsciencenews.com www.advhealthmat. de blockade, the efficiency of this strategy still remains to be improved. Efficient delivery of checkpoint inhibitors to the desired sites has been intensively studied.
Local Delivery of Checkpoint Inhibitors
Sustained and controlled delivery of checkpoint inhibitors to the sites of interest is a desirable strategy to minimize or eliminate limitations of immune checkpoint blockade while improving the therapeutic index. [15] Thus, strategies of local delivery of checkpoint inhibitors that can induce durable and specific antitumor immune responses in the tumor site have been developed by many groups. [16] For instance, Fransen et al. reported a delivery system that utilized Montanide ISA-51 to deliver anti-CTLA-4 to the tumor draining area, resulting in an effective antitumor immune response. Local delivery with a lower dose of anti-CTLA-4 worked as effectively as systemic delivery in inducing antitumor immunity. [16a] In addition to local delivery of anti-CTLA-4 antibody, Li et al. used an alginate hydrogel to deliver anti-PD-1 and celecoxib locally to the tumors, resulting in improved effector T cell immune responses, reduced immunosuppression and tumor angiogenesis. [17] In the studies of Gu group, a microneedle (MN) patch was used for local and sustained delivery of checkpoint inhibitors (Figure 1) . [16b] A self-degradable MN patch, which was consisted of biocompatible hyaluronic acid that incorporated pH-responsive dextran nanoparticles, achieved sustained and controllable delivery of anti-PD-1 antibodies at the tumor sites. The patch could penetrate the epidermis and sustainably release anti-PD-1 antibody in the tumor microenvironment. Compared to free antibody, they found that a single treatment of MN patch encapsulated with anti-PD-1 antibody induced intense immunologic responses in the B16F10 mouse melanoma models. After treatment, 50% of mice survived with undetectable tumors within 40 d. Moreover, the MN patch could also be used to simultaneously deliver anti-PD-1 antibody and other immune checkpoint inhibitors including anti-CTLA-4 antibodies or 1-methyl-DLtryptophan (1-MT), an inhibitor of IDO. [16c] A synergistic effect was obtained on the mouse melanoma tumor model after the combination delivery of different immune checkpoint inhibitors via MN patch.
Targeted Delivery of Checkpoint Inhibitors
In addition to local delivery of checkpoint inhibitors into tumor sites, targeted delivery of checkpoint inhibitors at the tumor sites is also urgently required but challenging. Traditionally, targeting ligands, which can bind to appropriate receptors overexpressed on tumor cells, need to be conjugated to the surface of nanocarriers to realize active targeting. [18] However, these receptors are usually not expressed homogeneously on cancer cells and the binding affinity is also often influenced by many factors. [19] Platelet, a kind of anucleate cell in the blood, can quickly migrate to the injured sites of vasculatures to stop bleeding. [20] Moreover, according to previous studies, platelets can also recognize and interact with circulating tumor cells, then recruiting and awaking immune cells including T cells. [21] Inspired by these unique properties of platelets, Wang et al. proposed utilizing platelets for targeted delivery of checkpoint inhibitors into tumor site after surgery (Figure 2) . [22] Specifically, anti-PD-L1 antibodies were conjugated to the surface of platelets. The platelets helped anti-PD-L1 antibody to target the circulating tumor cells as well as the tumor site after surgery. Of note, the anti-PD-L1 antibodies conjugated on the surface of platelets were released efficiently after the activation of platelets, probably due to the platelet-derived microparticles. Such platelets-anti-PD-L1 therapy significantly prolonged the survival of mice after surgery, and reduced the risk of cancer regrowth and metastasis. In a following work, [23] Zhang et al. engineered HEK 293T cells to stably express PD-1 receptors (Figure 3) . 
Combination Immune Checkpoint Blockade with Other Therapeutic Strategies
Considering the dynamic nature of immune responses at the tumor sites and the complicated regulation of immune checkpoints with their ligands, it may be challenging to rely on a sole immune checkpoint inhibitor for cancer immunotherapy in clinic. [5, 24] Thus, it is necessary to evaluate the combination of different checkpoint inhibitors or with other therapeutic strategies such as chemotherapy, radiotherapy, phototherapy, and other immunotherapies. [14, 25] Many of these combination strategies have achieved obviously synergistic therapeutic effects than a single treatment of CTLA-4 or PD-1/PD-L1 blockade.
Combination Immune Checkpoint Blockade with Phototherapy
Phototherapy is a class of noninvasive and novel therapeutic technique including photothermal therapy (PTT) and photodynamic therapy (PDT) with many superiorities such as improved selectivity, remote controllability, and low systemic toxicity. [26] Liu and co-workers found that photothermal ablation of primary tumors with single-walled nanotubes (SWNTs) could release debris from cancer cells, which could act as the tumor-associated antigen to induce strong antitumor immune responses. [27] The researchers found that SWNT-based PTT was able to greatly increase the efficiency of anti-CTLA-4 blockade by inhibiting the growth of distant established tumors. In a following work, Chen et al. used three FDA-approved agents, indocyanine green (ICG), imiquimod (R837), and poly(lactic-coglycolic) acid (PLGA), to form PLGA-ICG-R837 nanoparticles (Figure 4) . [28] Utilizing PLGA-ICG-R837-based PTT of the primary tumor, the released tumor-associated antigens in combination with nanoparticles generated strong antitumor immune responses. After combined with CTLA-4 checkpoint blockade, this strategy could attack the remaining cancer cells, thereby inhibiting cancer metastasis and relapse.
Immune checkpoint blockade can also be combined with PDT. [29] www.advancedsciencenews.com www.advhealthmat.de caused immunogenic cell death and released a large amount of tumor-associated antigens, which activated the immune system and recruited immune cells. Meanwhile, the released IDO inhibitors effectively inhibited IDO activity to activate the immune cells in the tumors. [29c] In their following work, [30] Znpyrophosphate (ZnP) nanoparticles loaded with pyrolipid, a lipid conjugated with a photosensitizer, were reported to induce necrosis and apoptosis of cancer cells under light irradiation, activate the adaptive and innate immunological responses, and sensitize the tumor to PD-L1 checkpoint blockade. In a recent work, Xu et al. designed a multifunctional upconversion nanoparticle (UCNP) loaded with chlorine6 (Ce6) and R837 for PDT of primary tumors. [31] After PDT treatment with these nanoparticles, the released tumor-associated antigens working together with anti-CTLA-4 antibodies effectively eliminated primary and metastatic tumors. In addition to utilizing monoclonal antibodies for checkpoint blockade, Wang et al. proposed genetic inhibition of PD-1/PD-L1 interaction by RNA interference. [32] Specifically, they prepared an acid-responsive micelleplex (POP−PD-L1) simultaneously loaded with the pheophorbide A photosensitizers and PD-L1 specific small interfering RNA (siRNA-PD-L1) ( Figure 5) . The POP-PD-L1 micelleplex successfully delivered the photosensitizer and siRNA-PD-L1 to the PD-L1 overexpressed tumors. Under the laser irradiation, 
Combination Immune Checkpoint Blockade with Radiotherapy
Radiotherapy (RT), utilizing ionizing radiation beams including high-energy X-ray and γ-ray to induce DNA damage and kill cancer cells, has been widely applied in clinic to treat 65-75% of solid tumors at different stages. [33] RT can induce various complex systemic effects including inflammation, distant effects, and immune responses. [34] Combination of RT and immune checkpoint blockade has been proven to be another important and effective approach to improve cancer immunotherapy. [35] For example, Victor et al. carefully investigated the immunological responses both in patients and mice after treated with radiation and anti-CTLA-4 antibody. [36] They found that CTLA-4 blockade obviously inhibited T-regulatory cells, while radiation diversified the T-cell receptor and recruited more T cells in the tumor. Addition of anti-PD-L1 antibody further suppressed the T-cell exhaustion, resulting in significantly improved therapeutic efficacy in patients. In another work, Min et al. reported a strategy utilizing the antigen-capturing PLGA nanoparticle (AC-NP)-based radiotherapy together with anti-PD-1 antibodies to improve cancer immunotherapy (Figure 6 ). [37] The researcher found that AC-NPs could effectively deliver tumor-associated antigens to antigen-presenting cells (APCs) and obviously enhance the efficacy of PD-1 checkpoint blockade on a B16F10 melanoma model. AC-NPs were demonstrated to improve the antitumor immune responses and induce the abscopal effect by capturing the released tumor-associated antigens during radiotherapy, thus greatly promoting anticancer immunity. The mechanism studies also revealed that AC-NPs could increase both expansion of CD8+ cytotoxic T cells and the ratios of CD4 + T/Treg and CD8 + T/Treg.
Combination Immune Checkpoint Blockade with Chemotherapy
In addition to phototherapy and radiotherapy, apoptosis of cancer cells induced by chemotherapeutic drugs, also called immunogenic cell death, can release considerable amount of damage-associated signals, which can be engulfed by antigen presenting cells such as DCs, triggering specific antitumor immune responses. [38] Chen et al. developed a multifunctional immunostimulatory nanomicellar carrier loaded with both paclitaxel, a therapeutic drug, and NLG919, an IDO inhibitor. [39] The paclitaxel-induced immunogenic death of cancer cells successfully activated the innate and adaptive immune systems. Moreover, the released NLG919 further improved the antitumor immune responses via blocking the IDO-mediated T cell suppression. In another work, Lu and coworkers also encapsulated the IDO inhibitor, indoximod, and the chemotherapeutic drug, oxaliplatin into the lipid-covered www.advancedsciencenews.com www.advhealthmat.de mesoporous silica nanoparticles, achieving a significant reduction or eradication of tumor by inducing the effective innate and adaptive antitumor immunity. [40] He et al. designed nanoscaled coordination polymer-based core-shell nanoparticles (NCP@pyrolipid) encapsulated with the photosensitizers and chemotherapeutic drugs for effective combined PDT and chemotherapy. [29b] They also discovered that the combination of PDT and chemotherapy against primary tumor caused the immunogenic environment in the tumor, which greatly facilitated the PD-L1 checkpoint blockade therapy, resulting in effective systemic antitumor immunity. Recently, Wang et al. engineered a novel reactive oxygen species (ROS) degradable scaffold for local delivery and slow release of gemcitabine (GEM) and anti-PD-L1 antibody (Figure 7) . [41] The researcher found that the released low dose of GEM could induce immunogenic tumor phenotype by upregulating PD-1 and PD-L1 on T cells and cancer cells, respectively. The ROS-responsive scaffold used in this work not only acted as reservoir for controlled release of therapeutics, but also eliminated ROS in the tumor to reverse the immunosuppressive tumor microenvironment. Thus, the GEM-aPD-L1 scaffold used in this work induced immunogenic tumor phenotype, promoted an effective antitumor immune activity, and inhibited tumor recurrence after surgery.
Combination Immune Checkpoint Blockade with Cancer Vaccine
Considerable attentions have been paid to cancer vaccines owning to their unique advantages such as good safety profiles, antigen-specific immunological responses, and effective immune memories. [42] However, effective antitumor immune responses not only demand the immune activation, but also require the reduction of immune suppressive or inhibitory pathways. [11b,43] Thus, combination of cancer vaccine and checkpoint inhibitors could enhance the effectiveness of the immune system to destroy cancers. [11a,44] Kuai et al. engineered high-density lipoprotein (sHDL)-mimicking nanodiscs, encapsulated with tumor antigen peptides and 5′-C-phosphate-G-3′ (CpG) motif, realizing codelivery of antigen (Ag) peptides and adjuvants to draining lymph nodes and prolonged Ag presentation to APCs (Figure 8) . [45] Thus, the multiepitope vaccination based on the sHDL-Ag/CpG generated extensive immune responses that potently inhibited tumor growth. Moreover, when combined with anti-CTLA-4 and anti-PD-1 antibodies, sHDL-Ag/CpG stimulated more effective CD8+ cytotoxic albumin binding vaccines (AlbiVax), which could self-assemble with endogenous albumin in vivo forming albumin/AlbiVax nanocomplexes for the effective vaccine delivery and immunotherapy. [46] After combination with anti-PD-1 treatment, AlbiVax significantly inhibited the tumor growth.
Conclusion
At the interface of immunology, cancer biology, molecular pharmaceutics, and drug delivery, many strategies and related formulations as well as devices have been developed to improve the therapeutic efficacy of immune checkpoint blockade for cancer therapy, as summarized in Table 1 . For example, developing a minimally invasive delivery approach that can realize sustained release of immune checkpoint blockade inhibitors, could help enhance the overall therapeutic outcomes and reduce risks of autoimmune diseases with limited activation of T cells in normal tissues. Seeking of biocompatible drug delivery carriers including inherent bioparticulates could be helpful to realize local or active targeted delivery of checkpoint blockade antibodies. [47] Furthermore, more efforts could be devoted to developing biomaterial-based carriers that can intrinsically activate both adaptive and innate immune systems to further improve the treatment effectiveness. Leveraging biomaterials and drug delivery systems for combination therapy is another important theme to overcome the limitations and improve the efficacy of ICB-based treatments. Many cancer treatment modalities, including phototherapy, chemotherapy, and radiotherapy, can create the immunogenic tumor environment including immunological cells death, releasing tumor-associated antigens, and eliciting immunogenic tumor phenotypes, which can increase the objective response rates of immune checkpoint inhibitors. Immune checkpoint blockade combined with vaccines, neoantigens, and other immunomodulators has also been developed and achieved promising results.
Further optimization of combination approaches should incorporate systemic evaluation effect of each component or modality and maximize the overall efficiency by varying therapeutic dose, treatment frequency, and duration.
To accelerate clinical translation of the described strategies, immunologists, oncologists, and bioengineers are expected to On days 1 and 4 after each vaccination, mice were administered intraperitoneally with anti-PD-1 (100 µg per mouse). Reproduced with permission. [45] Copyright 2017, Springer Nature. work together to close the gap of both technological and clinical demands. More and more exciting discoveries and inventions for enhanced ICB therapy are on the way. PD-1 receptor 293T cells [23] Combination therapy with other therapeutic strategies Anti-CTLA-4 Phototherapy (carbon nanotubes, indocyanine green, chlorin e6) [27, 28, 31] Radiotherapy (X-ray) [36] Chemotherapy (paclitaxel, carboplatin)
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